SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody

Conclusions
Stimulating the agrin-LRP4-MuSK-DOK7 AChR clustering pathway with NSC-87877, or other drugs, could represent a novel therapeutic approach for MuSK-MG and could potentially improve other NMJ disorders with reduced AChR numbers or disrupted NMJs.

Source: Neurology Neuroimmunology and Neuroinflammation - December 11, 2019 Category: Neurology Authors: Huda, S., Cao, M., De Rosa, A., Woodhall, M., Rodriguez Cruz, P. M., Cossins, J., Maestri, M., Ricciardi, R., Evoli, A., Beeson, D., Vincent, A. Tags: Myasthenia Article Source Type: research